MWM
CHRS icon

Meridian Wealth Management’s Coherus Oncology CHRS Stock Holding History

Meridian Wealth Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$221 – 239
2019
Q2 		$221 Buy
+1,000
New +$17.4K 0.01% 523

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Meridian Wealth Management's CHRS Position: Q3 2019 in Review

Meridian Wealth Management sold out of Coherus Oncology (CHRS) in Q3 2019, closing a stake of 1,000 shares — an estimated $221 sold.

Meridian Wealth Management first reported a position in CHRS in Q2 2019 and held it in 1 quarter. The position peaked at $221 in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

  • Meridian Wealth Management reported no remaining Coherus Oncology position as of Q3 2019 after selling out during the quarter.
  • Meridian Wealth Management sold 1,000 Coherus Oncology shares in Q3 2019, an estimated $221.
  • Meridian Wealth Management first reported a position in Coherus Oncology in Q2 2019 and held it in 1 quarter.
  • Meridian Wealth Management's Coherus Oncology position peaked at $221 in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Meridian Wealth Management's 13F filing for Q3 2019, filed 8 Nov 2019.